Heart Failure [ACCF/AHA]

Heart Failure

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/176034

Contents of this Issue

Navigation

Page 26 of 57

Drugs of Unproven Value or That May Worsen HF ÎÎNutritional supplements as treatment for HF are NOT recommended in patients with current or prior symptoms of HFr EF. (III-B: No Benefit) ÎÎHormonal therapies other than to correct deficiencies are NOT recommended for patients with current or prior symptoms of HFr EF. (III-C: No Benefit) ÎÎDrugs known to adversely affect the clinical status of patients with current or prior symptoms of HFr EF are potentially harmful and should be avoided or withdrawn whenever possible (eg, most antiarrhythmic drugs, most calcium channel–blocking drugs [except amlodipine], nonsteroidal anti-inflammatory drugs, or thiazolidinediones). (III-B: Harm) ÎÎLong-term use of infused positive inotropic drugs is potentially harmful for patients with HFr EF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment (see recommendations for stage D on page 32). (III-C: Harm) Calcium Channel Blockers ÎÎCalcium channel–blocking drugs are NOT recommended as routine treatment for patients with HFr EF. (III-A: No Benefit) 25

Articles in this issue

Archives of this issue

view archives of Heart Failure [ACCF/AHA] - Heart Failure